949904-48-7|Axelopran|3-[(1R,5S)-8-[2-[cyclohexylmethyl-[(2S)-2,3-dihydroxypropanoyl]amino]ethyl]-8-azabicyclo[3.2.1]octan-3-yl]benzamide|-范德生物科技公司

Axelopran

NMR下载 COA and HPLC MSDS下载
names：
3-[(1R,5S)-8-[2-[cyclohexylmethyl-[(2S)-2,3-dihydroxypropanoyl]amino]ethyl]-8-azabicyclo[3.2.1]octan-3-yl]benzamide
CAS号：
949904-48-7
MDL Number：
MF(分子式)： C26H39N3O4 MW(分子量)： 457.615
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Axelopran
英文别名	TD-1211; TD 1211; TD1211; Axelopran
CAS号	949904-48-7
Inchi	InChI=1S/C26H39N3O4/c27-25(32)20-8-4-7-19(13-20)21-14-22-9-10-23(15-21)29(22)12-11-28(26(33)24(31)17-30)16-18-5-2-1-3-6-18/h4,7-8,13,18,21-24,30-31H,1-3,5-6,9-12,14-17H2,(H2,27,32)/t21-,22+,23-,24-/m0/s1
InchiKey	ATLYLVPZNWDJBW-KIHHCIJBSA-N
分子式 Formula	C26H39N3O4
分子量 Molecular Weight	457.615
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Axelopran(CAS:949904-48-7 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Axelopran, also known as TD-1211, is a potent, selective, and peripherally-restricted μ-, κ-, and δ-opioid receptor antagonist, with similar affinity for the μ- and κ-opioid receptors and about an order of magnitude lower affinity for the δ-opioid receptor. Axelopran has potent μ-opioid receptor antagonist activity on the gastrointestinal tract in vivo, and thus it produces a dose-dependent inhibition of opioid-induced delaying in gastric emptying in mice and rats following subcutaneous or oral administration. Axelopran is potentially useful for the treatment of opioid-induced constipation.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Tsuruda PR, Vickery RG, Long DD, Armstrong SR, Beattie DT. The in vitropharmacological profile of TD-1211, a neutral opioid receptor antagonist. NaunynSchmiedebergs Arch Pharmacol. 2013 Jun;386(6):479-9[1]doi:10.1007/s00210-013-0850-7. Epub 2013 Apr 4. PubMed PMID: 23549670.

[2]Armstrong SR, Campbell CB, Richardson CL, Vickery RG, Tsuruda PR, Long DD,Hegde SS, Beattie DT. The in vivo pharmacodynamics of the novel opioid receptorantagonist, TD-1211, in models of opioid-induced gastrointestinal and CNSactivity. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386(6):471-8. doi:10.1007/s00210-013-0844-5. Epub 2013 Mar 13. PubMed PMID: 23512167.

[3] Diego L, Atayee R, Helmons P, Hsiao G, von Gunten CF. Novel opioid antagonistsfor opioid-induced bowel dysfunction. Expert Opin Investig Drugs. 2011Aug;20(8):1047-56. doi: 10.1517/13543784.2011.592830. Epub 2011 Jun 12. Review.PubMed PMID: 21663526.

[4] Camilleri M. Opioid-induced constipation: challenges and therapeuticopportunities. Am J Gastroenterol. 2011 May;106(5):835-42; quiz 843. doi:10.1038/ajg.2011.30. Epub 2011 Feb 22. Review. PubMed PMID: 21343919.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开